• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Matheis Dennis was granted 112,800 shares, increasing direct ownership by 226% to 162,725 units (SEC Form 4)

    2/21/25 5:19:24 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care
    Get the next $LUCD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Matheis Dennis

    (Last) (First) (Middle)
    360 MADISON AVENUE, 25TH FLOOR

    (Street)
    NEW YORK NY 10017

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Lucid Diagnostics Inc. [ LUCD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/20/2025 A 112,800(1) A $0 162,725 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed
    /s/ Michael A. Gordon, by power of attorney 02/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LUCD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUCD

    DatePrice TargetRatingAnalyst
    12/27/2021$16.00Buy
    Ascendiant Capital
    12/15/2021$17.00 → $13.00Buy
    Needham
    11/8/2021$18.00Buy
    Canaccord Genuity
    11/8/2021$14.00Buy
    BTIG Research
    11/8/2021$21.00Overweight
    Cantor Fitzgerald
    11/8/2021$17.00Buy
    Needham
    More analyst ratings

    $LUCD
    Leadership Updates

    Live Leadership Updates

    See more
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President

      Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the appointment of Gary Manning to the newly created position of President, Veris Health. Mr. Manning reports directly to Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer and Veris' Executive Chairman.

      4/25/23 8:45:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

      SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      12/12/24 4:30:32 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lucid Diagnostics Inc.

      SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      7/8/24 3:49:29 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Lucid Diagnostics Inc. (Amendment)

      SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      2/20/24 4:45:37 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO O'Neil Shaun was granted 300,000 shares, increasing direct ownership by 57% to 826,763 units (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      2/21/25 5:56:17 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Aklog Lishan was granted 300,000 shares, increasing direct ownership by 26% to 1,466,627 units (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      2/21/25 5:46:26 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Director Sokolov Jacque J was granted 112,800 shares, increasing direct ownership by 133% to 197,460 units (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      2/21/25 5:36:21 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    Financials

    Live finance-specific insights

    See more
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies  Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch  PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital

      3/25/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

      Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK, April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett's Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. These results support EsoGuard esophageal precancer testing in

      4/24/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Lucid Diagnostics Inc.

      DEFA14A - Lucid Diagnostics Inc. (0001799011) (Filer)

      4/30/25 4:17:10 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Lucid Diagnostics Inc.

      DEF 14A - Lucid Diagnostics Inc. (0001799011) (Filer)

      4/30/25 4:15:30 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Lucid Diagnostics Inc. (0001799011) (Filer)

      4/25/25 4:44:19 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target

      Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00

      12/27/21 6:21:16 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Needham reiterated coverage on Lucid Diagnostics with a new price target

      Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously

      12/15/21 6:36:10 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target

      Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00

      11/8/21 10:16:23 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care